Surrozen, Inc.
SRZN
NASDAQ·Healthcare·Biotechnology·Mkt cap $170.2M
$22.76
▲ +0.98%
P/E
-2.56
Mkt Cap
$170.2M
52-Wk Range
$11.25–$35.00
52-Week Range
$11.25 - $35.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 100.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+5.8% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SRZN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 6, 2026
Reported EPS of -$0.41 vs -$1.29 consensus (+68.2% surprise). Revenue of $5.0M vs $467.3K expected (+970.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+68.2%
Revenue trend · last 2Q
—
+409%
Q1 26
Q2 26
$5.0M
$5.0M
Margins · last 2Q
Gross
0.0%
Profit
0.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · $44.00 · May 7, 2026
vs Industry
How SRZN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.